OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - A GERCOR study

Journal of Clinical Oncology

Volumn 24, Issue 3, 2006, Pages 394-400

  Tournigand, Christophe ^a   Cervantes, Andres ^a   Figer, Arie ^a   Lledo, Gérard ^a   Flesch, Michel ^a   Buyse, Marc ^a   Mineur, Laurent ^a   Carola, Elisabeth ^a   Etienne, Pierre Luc ^a   Rivera, Fernando ^a   Chirivella, Isabel ^a   Perez Staub, Nathalie ^a   Louvet, Christophe ^a   André, Thierry ^a   Tabah Fisch, Isabelle ^a   de Gramont, Aimery ^a  

^a Saint Jean Clinic of Brussels   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; FOLFOX PROTOCOL; PLATINUM COMPLEX;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PARESTHESIA; PHLEBITIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG PULSE THERAPY; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PULSE THERAPY, DRUG; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644843853     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.0106     Document Type: Article

References (21)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
3. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
4. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
5. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
6. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
7. Maindrault-Goebel F, de Gramont A, Louvet C, et al: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000-1005, 2001
8. Maindrault-Goebel F, de Gramont A, Louvet C, et al: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer: Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11:1477-1483, 2000
9. Maindrault-Goebel F, Tournigand C, Andre T, et al: Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 15:1210-1214, 2004
10. National Cancer Institute: National Cancer Institute Common Toxicity Criteria, version 2.0.
11. Maindrault F, Louvet C, André T, et al: Time to disease control (TDC) to evaluate the impact on survival of three chemotherapy lines in metastatic colorectal cancer (MRC) based on 5-fluorouracil, oxaliplatin and irinotecan (GERCOR). Proc Am Soc Clin Oncol 20:146a, 2001 (suppl; abstr 581)
12. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 31:103-115, 1975
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Mantel NHW: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
15. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
16. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
17. Köhne C, Van Cutsem E, Wils JA, et al: Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of the EORTC GI Group Study 40986. Proc Am Clin Oncol 22:254, 2003 (suppl; abstr 1018)
18. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Clin Oncol 21:129a, 2002 (suppl; abstr 512)
19. Goldberg R, Sargent DJ, Morton RF, et al: N9741: FOLFOX (oxaliplatin (Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal, cancer (CRC): Final efficacy data from an intergroup study. J Clin Oncol 22:275s, 2004 (suppl; abstr 3621)
20. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
21. de Gramont A, Louvet C, André T, et al: Infusional 5-fluorouracil: The bimonthly approach, in Bleiberg H, Kemeny N, Rougier P, et al (eds): Colorectal Cancer: A Clinical Guide to Therapy. London, United Kingdom, Dunitz, 2002, pp 463-466